ArticleWorld journal of gastrointestinal oncology2022

Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio's prediction on effectiveness.

Yu-Jie Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.